Head-to-head evidence
BI 1569912 vs Zelquistinel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
BI 1569912
Developed by Boehringer Ingelheim
NCT06280235 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 243 participants, using the clinical MADRS depression score as its primary endpoint. However, the prespecified primary dose-response analysis was not statistically significant, so the trial provides well-controlled but inconclusive evidence of benefit.
Zelquistinel
Developed by Syndeio Biosciences
NCT03726658 · Phase 1/2 · completed
The study randomized 226 participants overall to several zelquistinel dose groups or placebo and masked both participants and investigators, but it stated that no power calculation was performed and each comparison was relatively small. The primary MADRS comparisons were clinical measures but were missed, with all reported p-values above 0.05, so the findings provide limited evidence of benefit.
Next expected readout: September 2027 · NCT06547489 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BI 1569912's landscape · Zelquistinel's landscape